ArticleAbdominal radiology (New York)2026
CT-based radiomics signature for optimizing adjuvant chemotherapy decisions in stage II colorectal cancer with proficient mismatch repair.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo develop a CT-based radiomics model for predicting prognosis and optimizing adjuvant chemotherapy (ACT) decisions in stage II proficient mismatch repair (pMMR) colorectal cancer (CRC).
methodsWe retrospectively enrolled 379 stage II pMMR CRC patients with distinctly good or poor outcomes, including 125 patients in the validation cohort. The radiomics model was developed using features extracted from segmented CT volumes by XGBoost. Clinical model A was constructed via multivariate logistic regression incorporating clinical factors recommended by the European Society of Medical Oncology (ESMO). Model performance was compared using the DeLong test. Survival analysis employed Kaplan-Meier curves and log-rank tests, and ACT subgroup analysis was performed according to risk stratification.
resultsIn the validation cohort, the radiomics model (AUC = 0.800) and combined model A (AUC = 0.811) outperformed clinical model A (AUC = 0.576; both p < 0.05). Patients stratified as low-risk by either the radiomics model or the combined model A exhibited significantly longer overall survival (OS) than high-risk patients in both training and validation cohorts (all p < 0.05). Within the high-risk groups identified by the radiomics model and the combined model A, patients receiving ACT showed significantly longer OS compared to non-recipients (p = 0.015 and p = 0.008, respectively), while no significant difference was observed in low-risk groups (both p > 0.05).
conclusionCompared to ESMO-recommended clinical high-risk factors, the CT-based radiomics model demonstrated superior prognostic prediction performance and could optimize ACT decisions based on risk stratification in stage II pMMR CRC.
Indexed as
Identifiers
41860707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.